Treatment of obese rhesus monkeys, which are a model for human obesity and its associated metabolic disorders, with the PPARβ/δ agonist GW501516 increased HDL-cholesterol (79%), and decreased triglycerides (56%), LDL-cholesterol (29%), and fasting insulin levels (48%) [22]. This evidence concerns the gene INS and obesity disorder.